Incyte Biosciences Canada
In April 2020, Christine Lennon became the first General Manager and employee for Incyte Biosciences Canada (Incyte (NASDAQ:INCY), expanding the Company’s North American footprint responsible for the development of Incyte’s medical, regulatory and commercial strategy in Canada.
Prior to joining Incyte, Christine was President and CEO of Epigene Therapeutics, a spinout of Neomed Therapeutics, now Admare Bioinnovations. Prior to that, she spent eight years with Novartis Pharmaceuticals in a variety of roles including Commercial Head, Solid Tumors/Rare Disorders, Novartis Oncology Canada; General Manager of Oncology, Novartis Ireland; and Head of Policy, Market Access, Stakeholder Relations, Novartis Oncology Canada. Christine has also held leadership roles with Neurochem, Shire (now Takeda), BioChem Pharma and worked with the National Research Council of Canada (NRC) on potential COVID-19 solutions as part of the NRC Industrial Research Assistance Program. Christine has also served as an advisor to life sciences startups and as an executive-in-residence and advisor to the healthcare venture capital teams at Business Development Bank of Canada (now Amplitude Ventures) and at Caisse de Dépôt et Placement du Québec (CDP) Capital.
Christine earned both her MBA and BSc from McGill University and her Institute of Corporate Directors designation (ICD.D) from Rotman School of Management, University of Toronto. Christine serves as a judge and mentor for McGill University’s Dobson Centre for Entrepreneurship and McGill’s Desautels MBA School; as a mentor for Women in Pharma and as a guest lecturer for University of Toronto Mississauga’s Institute for Management & Innovation. Christine is a McGill University Scarlet Key Award Recipient and, was named a Healthcare Businesswomen Association Luminary in 2022. Christine also serves as a Board member of Montréal inVivo and Innovative Medicines Canada (IMC).